Modafinil and antipsychotic-induced sedation.
John R
JR
DeQuardo
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D065731:Cytochrome P-450 CYP2C19; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced* / Q000188:drug therapy; D004347:Drug Interactions; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D000077408:Modafinil; D012559:Schizophrenia / Q000188:drug therapy* / Q000201:enzymology
D014150:Antipsychotic Agents; D001559:Benzhydryl Compounds; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D003024:Clozapine; D000077408:Modafinil